Monoclonal Antibody Collaboration and Licensing Deals 2016-2023
SUMMARY
Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of monoclonal antibody deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 925 monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2016.
Chapter 3 provides an overview of the leading monoclonal antibody deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific monoclonal antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.
Monoclonal Antibody Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of:
BENEFITS
Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of monoclonal antibody deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 925 monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2016.
Chapter 3 provides an overview of the leading monoclonal antibody deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific monoclonal antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse monoclonal antibody collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.
Monoclonal Antibody Collaboration and Licensing Deals includes:
- Trends in monoclonal antibody dealmaking in the biopharma industry
- Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
- The leading monoclonal antibody deals by value
- Most active monoclonal antibody licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
BENEFITS
Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse precision medicine in oncology collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Executive Summary
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN MONOCLONAL ANTIBODY DEALMAKING
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates
CHAPTER 3 – LEADING MONOCLONAL ANTIBODY DEALS
3.1. Introduction
3.2. Top monoclonal antibody deals by value
CHAPTER 4 – MOST ACTIVE MONOCLONAL ANTIBODY DEALMAKERS
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles
CHAPTER 5 – MONOCLONAL ANTIBODY CONTRACTS DEALMAKING DIRECTORY
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory
CHAPTER 6 – MONOCLONAL ANTIBODY DEALMAKING BY TECHNOLOGY TYPE
Deal directory
Deal directory – Monoclonal antibody deals by company A-Z
Deal directory – Monoclonal antibody deals by deal type
Deal directory – Monoclonal antibody deals by therapy area
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN MONOCLONAL ANTIBODY DEALMAKING
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates
CHAPTER 3 – LEADING MONOCLONAL ANTIBODY DEALS
3.1. Introduction
3.2. Top monoclonal antibody deals by value
CHAPTER 4 – MOST ACTIVE MONOCLONAL ANTIBODY DEALMAKERS
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles
CHAPTER 5 – MONOCLONAL ANTIBODY CONTRACTS DEALMAKING DIRECTORY
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory
CHAPTER 6 – MONOCLONAL ANTIBODY DEALMAKING BY TECHNOLOGY TYPE
Deal directory
Deal directory – Monoclonal antibody deals by company A-Z
Deal directory – Monoclonal antibody deals by deal type
Deal directory – Monoclonal antibody deals by therapy area
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Monoclonal antibody deals since 2016
Figure 2: Active monoclonal antibody dealmaking activity – 2016 - 2023
Figure 3: Monoclonal antibody deals by deal type since 2016
Figure 4: Monoclonal antibody deals by therapy area since 2016
Figure 5: Monoclonal antibody deals by industry sector since 2016
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2016
Figure 11: Most active monoclonal antibody dealmakers 2016 - 2023
Figure 12: Monoclonal antibody deals by technology type since 2016
Figure 1: Monoclonal antibody deals since 2016
Figure 2: Active monoclonal antibody dealmaking activity – 2016 - 2023
Figure 3: Monoclonal antibody deals by deal type since 2016
Figure 4: Monoclonal antibody deals by therapy area since 2016
Figure 5: Monoclonal antibody deals by industry sector since 2016
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2016
Figure 11: Most active monoclonal antibody dealmakers 2016 - 2023
Figure 12: Monoclonal antibody deals by technology type since 2016
